StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on BlossomHill Therapeutics (BLSM)

Wed, 30 Sep 2026 07:18:38 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $35.00 price target on BlossomHill Therapeutics (NASDAQ: BLSM).

The analyst commented: "Yesterday, BlossomHill presented preclinical data for BH-501284 across multiple models at the AACR Conference on Pancreatic Cancer. As highlighted in the poster presentation, BH-501284 demonstrated selective and potent inhibition of pERK and cell proliferation (see Figure 1 below). At relatively low doses, treatment induced tumor regression across pancreatic, lung, and colorectal cancer models harboring KRAS G12V, G12D, or G12C mutations. In a KRAS G12C lung cancer model, the pseudo-irreversible inhibitor BH-501284 produced tumor regression comparable to that observed with covalent,

BlossomHill shares preclinical data on pan-KRAS inhibitor BH-501284

Mon, 28 Sep 2026 07:00:16 -0400

BlossomHill Therapeutics, Inc. (Nasdaq: BLSM) presented preclinical data on its investigational pan-KRAS inhibitor, BH-501284, at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer in San Diego, held September 25-28, 2026.

BH-501284 is an orally bioavailable, non-covalent, pseudo-irreversible pan-KRAS inhibitor built on a novel Switch-II chemical scaffold. According to the company, the compound is designed to achieve prolonged and selective inhibition of KRAS mutations while sparing HRAS and NRAS.

Key findings from the preclinical data include a target residence time exceeding 54 hours in a surface plasmon resonance (SPR) study using GDP-state KRAS G12D protein. The compound demonstrated tumor regression

BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer

Mon, 28 Sep 2026 07:00:00 -0400

Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 2027

Novel Switch-II scaffold and pseudo-irreversible binding designed to enable prolonged, potent and selective inhibition of mutant KRAS to potentially achieve improved efficacy and tolerability

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced the

BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer

Mon, 28 Sep 2026 07:00:00 -0400

Novel Switch-II scaffold and pseudo-irreversible binding designed to enable prolonged, potent and selective inhibition of mutant KRAS to potentially achieve improved efficacy and tolerability

BlossomHill Therapeutics (BLSM) PT Raised to $40 at Guggenheim

Mon, 21 Sep 2026 06:40:21 -0400

(Updated - September 21, 2026 6:40 AM EDT)

Guggenheim analyst Michael Schmidt raised the price target on BlossomHill Therapeutics (NASDAQ: BLSM) to $40.00 (from $30.00) while maintaining a Buy rating.

The analyst commented: "We recently initiated coverage of BLSM following the company's August 2026 IPO. Today, BLSM reported 2Q26 results and provided a pipeline update consistent with recent disclosures. The company's most advanced asset, BH-30643, a novel macrocyclic pan-EGFR inhibitor, is advancing in the global Phase 1 SOLARA study, with plans to launch an initial pivotal Phase 2 study in EGFR C797S+ NSCLC early next year, in support of accelerated approval. Management

BlossomHill Therapeutics (BLSM) PT Raised to $40 at Guggenheim

Mon, 21 Sep 2026 06:40:21 -0400

(Updated - September 21, 2026 6:40 AM EDT)

Guggenheim analyst Michael Schmidt raised the price target on BlossomHill Therapeutics (NASDAQ: BLSM) to $40.00 (from $30.00) while maintaining a Buy rating.

Form 10-Q BlossomHill Therapeutics For: Jun 30

Fri, 18 Sep 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260918/27078229.html

Form 8-K BlossomHill Therapeutics For: Sep 18

Fri, 18 Sep 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260918/27078178.html

BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

Fri, 18 Sep 2026 07:00:00 -0400

Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering

Announced FDA Fast Track designation for BH-30643 for the treatment of advanced
EGFR C797S-positive NSCLC

SAN DIEGO, Sept. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced financial results for the second quarter 2026 and highlighted recent progress.

“We’ve achieved meaningful progress across our pipeline, as well as our significant corporate

BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

Fri, 18 Sep 2026 07:00:00 -0400

Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering

Announced FDA Fast Track designation for BH-30643 for the treatment of advanced
EGFR C797S-positive NSCLC

“We’ve achieved meaningful progress across our pipeline, as well as our significant corporate

Form 8-K BlossomHill Therapeutics For: Sep 15

Tue, 15 Sep 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260915/27061130.html

BlossomHill drug shows 45% response rate in hard-to-treat lung cancer

Tue, 15 Sep 2026 07:00:18 -0400

BlossomHill Therapeutics (Nasdaq: BLSM) reported updated data from its ongoing Phase 1/2 SOLARA trial of BH-30643, an investigational oral drug candidate for non-small cell lung cancer (NSCLC) patients with EGFR C797S resistance mutations. The data were presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer in Seoul, South Korea.

Among 40 patients with EGFR C797S-positive resistance to prior EGFR inhibitor treatment, with or without concurrent T790M, BH-30643 produced a 45% objective response rate (ORR) and an 88% disease control rate (DCR). At the time of efficacy follow-up, 63% of patients remained on treatment,

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASL

Tue, 15 Sep 2026 07:00:00 -0400

45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat population with no approved targeted therapies

BH-30643 demonstrated a favorable safety profile with low rates of dose reduction or discontinuation due to treatment-related adverse events

Presentation follows receipt of FDA Fast Track designation for BH-30643 for the treatment of advanced or metastatic EGFR C797S-positive NSCLC

SAN DIEGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASL

Tue, 15 Sep 2026 07:00:00 -0400

BH-30643 demonstrated a favorable safety profile with low rates of dose reduction or discontinuation due to treatment-related adverse events

Presentation follows receipt of FDA Fast Track designation for BH-30643 for the treatment of advanced or metastatic EGFR C797S-positive NSCLC

SAN DIEGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

Thu, 03 Sep 2026 07:00:00 -0400

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that it will present at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference.

Geoff Oxnard, M.D., Chief Medical Officer of BlossomHill will present at the RAS-Targeted Drug Development Summit, and Jean Cui, Ph.D., Founder, President and Chief Executive Officer of BlossomHill will present at the H.C. Wainwright conference. Dr.

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

Thu, 03 Sep 2026 07:00:00 -0400

BlossomHill to present BH-30643 trial data at lung cancer conference

Tue, 01 Sep 2026 07:00:42 -0400

BlossomHill Therapeutics, Inc. (Nasdaq: BLSM) announced it will present updated data from its ongoing Phase 1/2 SOLARA trial of BH-30643 at the 2026 World Conference on Lung Cancer in Seoul, South Korea, on September 15, 2026.

The presentation, delivered as a mini-oral session, will cover anti-tumor activity of BH-30643 in patients with secondary epidermal growth factor receptor (EGFR) resistance mutations, including EGFR C797S. Dr. Hidehito Horinouchi of the National Cancer Center Hospital in Tokyo will present the data.

BH-30643 is an investigational oral, non-covalent, macrocyclic EGFR inhibitor being studied in EGFR-mutant non-small cell lung cancer (NSCLC). The FDA granted the drug Fast

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Canc

Tue, 01 Sep 2026 07:00:00 -0400

Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S

BH-30643 was recently granted Fast Track designation by the FDA for the treatment of C797S-positive resistance in EGFR-mutant NSCLC, a setting where no oral targeted therapies are approved

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Canc

Tue, 01 Sep 2026 07:00:00 -0400

Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S

BH-30643 was recently granted Fast Track designation by the FDA for the treatment of C797S-positive resistance in EGFR-mutant NSCLC, a setting where no oral targeted therapies are approved

LifeSci Capital Starts BlossomHill Therapeutics (BLSM) at Outperform

Tue, 01 Sep 2026 06:20:47 -0400

LifeSci Capital initiates coverage on BlossomHill Therapeutics (NASDAQ: BLSM) with a Outperform rating and a price target of $32.00.

For an analyst ratings summary and ratings history on BlossomHill Therapeutics click here. For more ratings news on BlossomHill Therapeutics click here.

Shares of BlossomHill Therapeutics closed at $18.30 yesterday.

H.C. Wainwright Starts BlossomHill Therapeutics (BLSM) at Buy

Tue, 01 Sep 2026 06:13:34 -0400

H.C. Wainwright analyst Robert Burns initiates coverage on BlossomHill Therapeutics (NASDAQ: BLSM) with a Buy rating and a price target of $35.00.

For an analyst ratings summary and ratings history on BlossomHill Therapeutics click here. For more ratings news on BlossomHill Therapeutics click here.

Shares of BlossomHill Therapeutics closed at $18.30 yesterday.

Guggenheim Starts BlossomHill Therapeutics (BLSM) at Buy

Tue, 01 Sep 2026 06:08:06 -0400

Guggenheim analyst Michael Schmidt initiates coverage on BlossomHill Therapeutics (NASDAQ: BLSM) with a Buy rating and a price target of $30.00.

For an analyst ratings summary and ratings history on BlossomHill Therapeutics click here. For more ratings news on BlossomHill Therapeutics click here.

Shares of BlossomHill Therapeutics closed at $18.30 yesterday.

JPMorgan Starts BlossomHill Therapeutics (BLSM) at Overweight

Tue, 01 Sep 2026 02:43:22 -0400

JPMorgan analyst Brian Cheng initiates coverage on BlossomHill Therapeutics (NASDAQ: BLSM) with a Overweight rating and a price target of $28.00.

The analyst comments: “We are initiating coverage of BlossomHill Therapeutics (BLSM) with an Overweight rating and a Dec-2027 price target of $28. BLSM is a clinical-stage oncology company leveraging management’s valuable know-how to design therapeutics with unique structural attributes. The company is blossoming into a maturing pipeline story led by a macrocyclic EGFR inhibitor called BH-30643. With resistance mutations like C797S moving into the mainstream in EGFRm NSCLC, we believe the lead ‘643 EGFRm program is poised to establish a

JPMorgan Starts BlossomHill Therapeutics (BLSM) at Overweight

Tue, 01 Sep 2026 02:43:22 -0400

JPMorgan analyst Brian Cheng initiates coverage on BlossomHill Therapeutics (NASDAQ: BLSM) with a Overweight rating and a price target of $28.00.

Form SCHEDULE 13D BlossomHill Therapeutics Filed by: ORBIMED ADVISORS LLC

Tue, 18 Aug 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260818/26945146.html